A U.S. appeals court has affirmed a lower ruling that Celltrion’s biosimilar to Johnson & Johnson’s (JNJ -1.9%) Remicade (infliximab) does not infringe on the latter’s patent covering the cell culture used in manufacturing.
Related ticker: Pfizer (PFE -2.3%)
https://seekingalpha.com/news/3549051-j-and-j-on-short-end-of-remicade-patent-ruling
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.